Larimar to kick off higher dose of lead rare disease drug, initiate OLE trial
The FDA gave Larimar Therapeutics the go-ahead to introduce a higher dose of its Friedreich’s ataxia treatment in a Phase II study.
The biotech announced Tuesday that the company can now use 50 mg doses of its lead drug, also known as CTI-1601, in the study. The 12 to 15 adult patients Larimar plans to enroll in that cohort will be randomized to either the drug or placebo, then dosed every day for the first two weeks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.